NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Quris Earns Frost & Sullivan 2022 European Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction - Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities - Quris.ai
Quris Earns Frost & Sullivan 2022 European Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction

 

NewswireTODAY - /newswire/ - San Antonio, TX, United States, 2022/08/31 - Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities - Quris.ai.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan recently researched the artificial intelligence (AI)-enabled drug safety prediction technology industry and, based on its findings, recognizes Quris with the 2022 Europe Technology Innovation Leadership Award. The innovative Quris Bio-AI Clinical Prediction Platform is the first AI breakthrough to close the clinical prediction gap by effectively predicting which drug candidates will work safely in humans.

“Quris AI Chip-on-Chip platform, unlike other AI-pharma solutions focusing on drug discovery, better indicates which drug candidates will safely work in humans. It uses AI to predict a drug’s safety, and hence its ability to succeed, particularly in Phase 1 trials, thus avoiding the high costs of failed clinical trials for pharmaceutical companies,” said Supriya Lala Kundu, a Best Practices Research analyst at Frost & Sullivan.

The company’s platform scales to fit the intricacies of clinical prediction, requiring machine learning (ML) models to routinely run a vast number of biological Patients-on-a-Chip experiments for AI training. Quris’s AI Chip-on-Chip technology leverages a patented process to test thousands of known safe and unsafe drugs on thousands of miniaturized Patients-on-a-Chip applying an automated, high-throughput system. Similarly, next-generation nano-sensors enable continuous response monitoring from each miniaturized organ to these drugs. Moreover, continuous data generation further trains the ML classification algorithm, making it highly predictive of clinical safety and enabling it to better discern the toxicity level of new drug candidates during testing. The innovative and ground-breaking platform simulates a natural human body’s reaction to novel molecules without relying on inaccurate animal testing reducing animal cruelty during pre-clinical experimentation due to its potential to limit dependence on animal testing.

Ashish Kaul, an industry analyst for Frost & Sullivan, said,“Unlike other organ-chip devices with limited ability to run millions of experiments, the Quris platform is highly scalable, enabling massive experiments to run cost-effectively and train the AI, thereby revolutionizing the pharmaceutical industry. Additionally, the platform can scale up to 1,000 drugs across all therapeutics, notably oncology, rare disease, and the blood-brain barrier.”

Quris stands out from competitors based on its commitment to innovation and creativity while achieving commercial success. In addition to its drug safety prediction pharma services, Quris also has a drug pipeline and provides personalized medicine services. The company has a team of scientists, technology experts, medical pioneers, and seasoned management professionals with a track record of seamless execution. Its strong intellectual property portfolio protects its pioneering technology, adding value relative to its growth potential, thus securing a competitive advantage. Its first AI-based Fragile-X drug is preparing for clinical testing later in 2022. Additionally, the company has established stem cell centers worldwide to provide personalized medicine services, further validating its platform and enabling it to grow through strategic partnerships with industry and research institutes.

“Recognition by the Frost & Sullivan team further validates our mission to completely rethink drug development and solve the biggest drug discovery challenge of our era using AI clinical prediction to remove longstanding barriers for the entire pharma industry. Allowing the efficient discovery of new drugs and the repurposing/personalization of existing drugs, Quris will help pharma companies avoid the tremendous risks and costs of failed clinical trials and end the reliance on ineffective animal testing,” added Quris Founder and CEO Isaac Bentwich.

Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

About Quris Technologies Ltd

Quris (quris.ai), the world’s first Bio-AI clinical-prediction platform ensures the safety and efficacy of new drugs. Revolutionizing the drug development process, the company is pioneering clinical trials on chips testing thousands of novel drug candidates on hundreds of miniaturized “patients-on-a-chip”. Its fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost effectively than ever before all while minimizing animal testing. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris is led by a proven team of AI and medical research powerhouses who are already preparing its lead discovery for clinical trials.

Contact:
Erica Camilo
P: 1-610-639-5644 - E: erica[.]connexacommunications.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Engineering / Artificial Intelligence articles,
CATCH Visitors via Your Competitors Announcements!


Quris Earns Frost & Sullivan 2022 European Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Quris Technologies Ltd | Frost & Sullivan
Contact: Kristen Moore - Frost.com 
210-247-3823 kristen.moore[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Engineering / Artificial Intelligence via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Engineering / Artificial Intelligence Most Recent Related Newswires:

inVia Robotics Earns Frost & Sullivan’s 2022 North American Technology Innovation Leadership Award for its Highly Differentiated Products and Robotics
Eurotech Announces the First IEC 62443-4-2 Security Certified Edge AI Gateway for Road Transportation and Fleet Management
Snapdragon Drives the Future of Mobile Computing with Industry-Leading AI Innovation for Windows 11
NEC and Virginia Tech Transportation Institute Demonstrate Intersection Safety Using AI-based Video Analytics
MetrixLab Adds AI Solution to its Market-leading Pack Design Testing Suite
Innowatts Recognized by Frost & Sullivan for Data-enabled Transformative Approach and Service to Energy Providers and Consumers
Oracle and NVIDIA Partner to Speed AI Adoption for Enterprises
Siemens Boosts Collaboration and Performance with Solid Edge 2023
XSENSOR Earns the Frost & Sullivan 2022 Technology Innovation Leadership Award for Intelligent Dynamic Sensing Systems
Mercedes-Benz and Qualcomm Collaborate to Power Upcoming Mercedes Vehicles with Snapdragon Digital Chassis Solutions
AmplifAI Earns Frost & Sullivan’s 2022 Competitive Strategy Leadership Award for its Advanced Performance Enablement Solutions
Alstom Opens New Engineering and Innovation Centre in Portugal
Smart Eye and STMicroelectronics Demonstrate High-sensitivity, Lower-cost, 1-LED Driver Monitoring System
RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely with its RapidAI Platform
AI Adoption Generates New Business Models and Strengthens Customer Value Says Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)